{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:51:50Z","timestamp":1790380310495,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.metabol.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T21:18:13Z","timestamp":1492118293000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study"],"prefix":"10.1016","volume":"72","author":[{"given":"Karlijn J.","family":"Nass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2703-2320","authenticated-orcid":false,"given":"Eline H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas Nico","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim C.M.A.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Blokzijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P.F.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2017.04.004_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","article-title":"Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese","volume":"121","author":"Dixon","year":"2001","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2017.04.004_bb0010","first-page":"S5","article-title":"The epidemiology of nonalcoholic fatty liver disease in adults","volume":"40","author":"Clark","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0015","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1464-5491.2005.01748.x","article-title":"Recent concepts in non-alcoholic fatty liver disease","volume":"22","author":"Adams","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2017.04.004_bb0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.metabol.2016.01.013","article-title":"Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet?","volume":"65","author":"Alkhouri","year":"2016","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2017.04.004_bb0025","doi-asserted-by":"crossref","first-page":"e0171502","DOI":"10.1371\/journal.pone.0171502","article-title":"Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: a large Dutch population cohort","volume":"12","author":"van den Berg","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2017.04.004_bb0030","doi-asserted-by":"crossref","first-page":"017","DOI":"10.1055\/s-2001-12926","article-title":"Clinical features and natural history of nonalcoholic steatosis syndromes","volume":"21","author":"Falck-Ytter","year":"2001","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.metabol.2017.04.004_bb0035","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/beem.2002.0225","article-title":"Obesity and liver disease","volume":"16","author":"Scheen","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.04.004_bb0040","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/j.1572-0241.2006.00719.x","article-title":"Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD","volume":"101","author":"Kang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0045","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.2337\/diabetes.54.11.3140","article-title":"Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study","volume":"54","author":"Hanley","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2017.04.004_bb0050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","article-title":"Insulin resistance: a metabolic pathway to chronic liver disease","volume":"42","author":"Bugianesi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2017.04.004_bb0055","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2337\/dc06-0455","article-title":"Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes","volume":"29","author":"Toledo","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.04.004_bb0060","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2015-3111","article-title":"Hepatic steatosis and insulin resistance, but not steatohepatitis, promote Atherogenic dyslipidemia in NAFLD","volume":"101","author":"Bril","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.04.004_bb0065","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jgh.12077","article-title":"Apolipoprotein B\/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects","volume":"28","author":"Choe","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0070","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacl.2015.12.026","article-title":"Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol","volume":"10","author":"Wu","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.04.004_bb0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2796.2010.02323.x","article-title":"Apolipoprotein B\/A-I and total cholesterol\/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein","volume":"269","author":"Kappelle","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.metabol.2017.04.004_bb0085","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2017.04.004_bb0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2017.04.004_bb0095","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.2337\/dc07-1088","article-title":"Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state","volume":"30","author":"Cali","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.04.004_bb0100","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/liv.13076","article-title":"Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease","volume":"36","author":"Jiang","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2017.04.004_bb0105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2014.05.023","article-title":"Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia","volume":"61","author":"Di Filippo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0110","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jhep.2012.07.030","article-title":"Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro","volume":"57","author":"Pirazzi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0115","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1007\/s10620-007-9740-5","article-title":"Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease","volume":"52","author":"Demirag","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.metabol.2017.04.004_bb0120","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1007\/s10620-008-0271-5","article-title":"Association of Apolipoprotein E Polymorphisms in patients with non-alcoholic steatohepatitis","volume":"53","author":"Sazci","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.metabol.2017.04.004_bb0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrendo.2010.50","article-title":"Diagnosis and treatment of apolipoprotein B dyslipoproteinemias","volume":"6","author":"Sniderman","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0130","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ncpendmet0982","article-title":"A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias","volume":"4","author":"de Graaf","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.04.004_bb0135","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2017.04.004_bb0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MEG.0000000000000254","article-title":"Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease","volume":"27","author":"Luo","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0145","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/ATVBAHA.114.303034","article-title":"Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease","volume":"34","author":"Byrne","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0150","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.3748\/wjg.v11.i31.4838","article-title":"Sonographic fatty liver, overweight and ischemic heart disease","volume":"11","author":"Lin","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0155","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jhep.2010.04.030","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes","volume":"53","author":"Targher","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0160","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2337\/dc06-2247","article-title":"Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2017.04.004_bb0165","first-page":"1172","article-title":"Cohort profile: LifeLines, a three-generation cohort study and biobank","volume":"44","author":"Scholtens","year":"2015"},{"key":"10.1016\/j.metabol.2017.04.004_bb0170","doi-asserted-by":"crossref","first-page":"e0137203","DOI":"10.1371\/journal.pone.0137203","article-title":"Representativeness of the LifeLines cohort study","volume":"10","author":"Klijs","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2017.04.004_bb0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10654-007-9204-4","article-title":"Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study","volume":"23","author":"Stolk","year":"2008","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0180","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0190","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2017.04.004_bb0195","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrgastro.2013.175","article-title":"Noninvasive evaluation of NAFLD","volume":"10","author":"Castera","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0200","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2017.04.004_bb0205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2017.04.004_bb0210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2017.04.004_bb0215","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2362.2010.02426.x","article-title":"Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study","volume":"41","author":"Holewijn","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2017.04.004_bb0220","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.3748\/wjg.v22.i31.7006","article-title":"Metabolic aspects of adult patients with nonalcoholic fatty liver disease","volume":"22","author":"Abenavoli","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0225","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0230","first-page":"685","article-title":"Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study","volume":"30","author":"Duvillard","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2017.04.004_bb0235","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1161\/01.ATV.17.12.3542","article-title":"Lipoprotein heterogeneity and apolipoprotein B metabolism","volume":"17","author":"Packard","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0240","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2017.04.004_bb0245","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2017.04.004_bb0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2017.04.004_bb0255","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0033-1358519","article-title":"Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease","volume":"33","author":"Cohen","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.metabol.2017.04.004_bb0260","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cca.2017.01.008","article-title":"Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: interrelationship with age","volume":"466","author":"Kunutsor","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2017.04.004_bb0265","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:12:44Z","timestamp":1758427964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517301129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":53,"alternative-id":["S0026049517301129"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.04.004","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}